The trial will examine whether a centralized Prevention Health & Cardiovascular Risk Service (PHCVRS) run by clinical pharmacists at the University of Iowa can be implemented in primary care offices and whether it can improve the care delivered to patients at risk for developing cardiovascular disease. The study will be conducted in 12 medical practices in Iowa that are either a Federally Qualified Health Center or part of the IRENE practice-based research network.
- PHCVRS Intervention Other
Intervention Desc: A clinical pharmacist at the PHCVRS will follow each participant in the PHCVRS arm for 12 months, including: Contact via email, phone or text every 2-4 weeks Assessment and counseling for medication adherence, side effects, and lifestyle modifications to decrease risk of cardiovascular disease. Collaborative communication with the participant's physician to address gaps in screening or therapy, update medication list, and recommend medication changes. Each participant in this arm will also have access to an online Personal Health Record that can be used to track medications, diagnosed conditions and laboratory values related to cardiovascular disease risk. ARM 1: Kind: Experimental Label: PHCVRS intervention Description: Each participant will receive communication with a clinical pharmacist for 12 months to decrease risk of developing cardiovascular disease.
- Personal Health Record Other
Intervention Desc: Participant will be able to access an online Personal Health Record for tracking medications and diagnosed conditions ARM 1: Kind: Experimental Label: PHCVRS intervention Description: Each participant will receive communication with a clinical pharmacist for 12 months to decrease risk of developing cardiovascular disease. ARM 2: Kind: Experimental Label: Usual care/Personal Health Record Description: Will receive usual medical care plus access to an online Personal Health Record, where the participant can document medications and diagnosed conditions.
- Allocation: Randomized
- Masking: Open Label
- Purpose: Treatment
- Intervention: Parallel Assignment
|Type||Measure||Time Frame||Safety Issue|
|Primary||Adherence of medical regimen/treatment to all of the Guideline Advantage criteria that apply.||12 months for each participant||No|
|Secondary||Control of blood pressure, low density lipoprotein cholesterol and hemoglobin A1c.||12 months for each participant||No|